Wegovy, a new anti-obesity drug from the Novo Nordisk laboratory, is now available in pharmacies in France. This treatment arouses strong interest but its use remains very restricted.
Wegovy has been marketed in France since October 8, 2024. This semaglutide-based drug, already authorized in around fifteen countries, is indicated for adults and adolescents over 12 years of age suffering from severe obesity. Its use is subject to strict conditions:
CONDITIONS OF USE AND CONCERNED AUDIENCE
- Initial prescription reserved for doctors specializing in endocrinology or nutrition
- Intended for patients under 65 years of age with a BMI of at least 35
- Used as a second intention, after failure of a first treatment
- Requires follow-up by obesity specialists
Wegovy is not reimbursed at this time. Its price, freely set by the laboratory, is estimated between 270 and 360 euros per month.
OPERATION AND EFFECTS
Semaglutide, the active ingredient in Wegovy, mimics an intestinal hormone promoting satiety. Patients lose an average of 15% of their initial weight after one year of treatment. Cardiovascular benefits have also been observed.
SIDE EFFECTS AND WARNING
The most common side effects are:
- Nausea
- Abdominal pain
- Vomiting
- Fatigue
More serious effects such as intestinal obstructions or pancreatitis are also possible. Health authorities are strengthening monitoring of this medication, particularly regarding long-term risks and potential misuse.
Related News :